• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oculis Holding AG - Ordinary shares (NQ:OCS)

    27.77 +0.29 (+1.06%)
    Streaming Delayed Price Updated: 9:49 AM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,560
    Open 27.40
    Bid (Size) 27.67 (100)
    Ask (Size) 27.99 (200)
    Prev. Close 27.48
    Today's Range 27.24 - 27.86
    52wk Range 16.00 - 30.68
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Publishes Invitation to the Annual General Meeting
    From Oculis Holding AG
    Via GlobeNewswire

    Performance

    YTD
    +38.9%
    +38.9%
    1 Month
    +4.3%
    +4.3%
    3 Month
    -4.3%
    -4.3%
    6 Month
    +42.6%
    +42.6%
    1 Year
    +47.2%
    +47.2%

    More News

    Read More
    News headline image
    Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Participate in Upcoming Investor Conferences
    From Oculis Holding AG
    Via GlobeNewswire
    Oculis Holding AG (NASDAQ:OCS) Reports Q4 2025 Earnings Beat, Focus Remains on 2026 Clinical Catalysts ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Participate in Upcoming Investor Conferences
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Appoints Katie Kazem as Chief Legal Officer
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Via Benzinga
    News headline image
    Oculis Holding AG (NASDAQ:OCS) Reports Q3 2025 Earnings Beat and Provides Key Clinical Pipeline Updates ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Oculis Reports Q3 2025 Financial Results and Provides Company Update
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Participate in Upcoming November Investor Conferences
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
    Via Benzinga
    News headline image
    Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Participate in Upcoming September Investor Conferences
    From Oculis Holding AG
    Via GlobeNewswire

    Frequently Asked Questions

    Is Oculis Holding AG - Ordinary shares publicly traded?
    Yes, Oculis Holding AG - Ordinary shares is publicly traded.
    What exchange does Oculis Holding AG - Ordinary shares trade on?
    Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Oculis Holding AG - Ordinary shares?
    The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
    What is the current price of Oculis Holding AG - Ordinary shares?
    The current price of Oculis Holding AG - Ordinary shares is 27.77
    When was Oculis Holding AG - Ordinary shares last traded?
    The last trade of Oculis Holding AG - Ordinary shares was at 05/04/26 09:49 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.